Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

ABSTRACT:

Background

A substantial unmet medical need exists for patients with Multiple Myeloma ineligible for autologous stem cell transplantation who relapse after first-line therapy with daratumumab, lenalidomide and dexamethasone (DRd). Three therapeutic options recommended for lenalidomide-refractory patients from EHA-ESMO guidelines are approved in Europe and reimbursed in Italy: carfilzomib and dexamethasone (Kd); pomalidomide, bortezomib and dexamethasone (PVd); selinexor, bortezomib and dexamethasone (SVd). This study aimed to identify key decision criteria and their relevance for assessing these alternatives from a multi-stakeholder perspective.

Methods

Following ISPOR good practices, we developed a multiple-criteria decision analysis framework using the Measuring Attractive

SUBMITTER: Boccadoro M 

PROVIDER: S-EPMC12577122 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature